Supernus Pharmaceuticals, Inc. (SUPN)
43.53
-0.44
(-1.00%)
USD |
NASDAQ |
Sep 04, 16:00
43.54
+0.01
(+0.02%)
After-Hours: 20:00
Supernus Pharmaceuticals SG&A Expense (TTM) : 560.88M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 560.88M |
| March 31, 2026 | 520.79M |
| December 31, 2025 | 485.56M |
| September 30, 2025 | 442.58M |
| June 30, 2025 | 332.66M |
| March 31, 2025 | 325.01M |
| December 31, 2024 | 321.58M |
| September 30, 2024 | 323.46M |
| June 30, 2024 | 336.40M |
| March 31, 2024 | 337.28M |
| December 31, 2023 | 336.36M |
| September 30, 2023 | 329.05M |
| June 30, 2023 | 358.66M |
| March 31, 2023 | 372.36M |
| December 31, 2022 | 377.22M |
| September 30, 2022 | 404.98M |
| June 30, 2022 | 364.70M |
| March 31, 2022 | 333.76M |
| December 31, 2021 | 304.76M |
| September 30, 2021 | 259.52M |
| June 30, 2021 | 242.15M |
| March 31, 2021 | 220.72M |
| December 31, 2020 | 202.14M |
| September 30, 2020 | 181.36M |
| June 30, 2020 | 167.35M |
| Date | Value |
|---|---|
| March 31, 2020 | 160.33M |
| December 31, 2019 | 158.42M |
| September 30, 2019 | 164.75M |
| June 30, 2019 | 164.99M |
| March 31, 2019 | 164.01M |
| December 31, 2018 | 159.89M |
| September 30, 2018 | 151.60M |
| June 30, 2018 | 151.54M |
| March 31, 2018 | 146.52M |
| December 31, 2017 | 137.90M |
| September 30, 2017 | 133.20M |
| June 30, 2017 | 118.05M |
| March 31, 2017 | 109.09M |
| December 31, 2016 | 106.01M |
| September 30, 2016 | 100.52M |
| June 30, 2016 | 97.75M |
| March 31, 2016 | 94.82M |
| December 31, 2015 | 89.06M |
| September 30, 2015 | 83.52M |
| June 30, 2015 | 77.96M |
| March 31, 2015 | 74.34M |
| December 31, 2014 | 72.47M |
| September 30, 2014 | 69.68M |
| June 30, 2014 | 66.95M |
| March 31, 2014 | 59.58M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Indivior Pharmaceuticals, Inc. | 591.00M |
| Pfizer Inc. | 13.72B |
| Amphastar Pharmaceuticals, Inc. | 139.25M |
| Collegium Pharmaceutical, Inc. | 327.69M |
| Bristol Myers Squibb Co. | 7.413B |